What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cold Spring Harbor Perspectives in Biology

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/cshperspect.a028902PMID 28348035PMCID PMC5880166
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunology

  2020cited by this paper
• A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

  2017cited by this paper
• Characterizing Ebola Transmission Patterns Based on Internet News Reports.

  2016cited by this paper
• Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

  2016cited by this paper
• Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

  2016cited by this paper
• A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

  2016influential reference
• IgG Binding Characteristics of Rhesus Macaque FcγR

  2016cited by this paper
• Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection

  2016cited by this paper
• Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

  2016cited by this paper
• Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses

  2016cited by this paper
• Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

  2016cited by this paper
• Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.

  2016cited by this paper
• Ebola vaccine trials: a race against the clock.

  2015cited by this paper
• The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field

  2015cited by this paper
• Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.

  2015cited by this paper
• Animal models in HIV-1 protection and therapy

  2015cited by this paper
• Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

  2015cited by this paper
• Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain

  2015influential reference
• Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.

  2015cited by this paper
• HIV-1 vaccine immunogen design strategies

  2015cited by this paper
• VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

  2015influential reference
• The modern era of HIV-1 vaccine development

  2015cited by this paper
• Development of SHIVs with circulating, transmitted HIV‐1 variants

  2015cited by this paper
• Ebola vaccine trials: a race against the clock

  2015cited by this paper
• Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

  2015cited by this paper
• Immunology of protection from Ebola virus infection

  2015cited by this paper
• A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

  2015cited by this paper
• Approaches to demonstration of Ebola virus vaccine efficacy.

  2015cited by this paper
• Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses

  2015influential reference
• Structures of protective antibodies reveal sites of vulnerability on Ebola virus

  2014cited by this paper
• Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies

  2014cited by this paper
• Immune Activation with HIV Vaccines

  2014cited by this paper
• Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

  2014cited by this paper
• Immune Activation with HIV Vaccines

  2014cited by this paper
• Mutations in HIV-1 Envelope That Enhance Entry with the Macaque CD4 Receptor Alter Antibody Recognition by Disrupting Quaternary Interactions within the Trimer

  2014cited by this paper
• Increased Mucosal CD4+ T Cell Activation in Rhesus Macaques following Vaccination with an Adenoviral Vector

  2014cited by this paper
• Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

  2014cited by this paper
• The Western Africa Ebola Virus Disease Epidemic Exhibits Both Global Exponential and Local Polynomial Growth Rates

  2014cited by this paper
• TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.

  2014cited by this paper
• Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins.

  2014cited by this paper
• CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants

  2014cited by this paper
• Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

  2014cited by this paper
• Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose

  2014influential reference
• Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

  2014cited by this paper
• Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains

  2014cited by this paper
• Pathology of Experimental Aerosol Zaire Ebolavirus Infection in Rhesus Macaques

  2013influential reference
• Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis

  2013influential reference
• Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

  2013cited by this paper
• Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease

  2012cited by this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cited by this paper
• Licensure of vaccines using the Animal Rule.

  2012cited by this paper
• Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages

  2012cited by this paper
• Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates

  2012cited by this paper
• Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

  2011cited by this paper
• Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.

  2011cited by this paper
• CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

  2011cited by this paper
• Establishing Efficacy of Human Products Using Animals

  2010influential reference
• Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

  2010cited by this paper
• Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens

  2009cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies

  2009cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

  2008cited by this paper
• Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

  2008cited by this paper
• Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239

  2006cited by this paper
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

  2005cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.

  2003cited by this paper
• Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.

  2003cited by this paper
• Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

  2002cited by this paper
• Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

  2002cited by this paper
• Marburg and Ebola virus infections in laboratory non-human primates: a literature review.

  2000cited by this paper
• Filovirus diseases.

  1999cited by this paper
• Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival.

  1999cited by this paper
• Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure.

  1999cited by this paper
• Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996.

  1999cited by this paper
• Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

  1998cited by this paper
• Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

  1996cited by this paper
• Development

  1996cited by this paper
• Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

  1995cited by this paper
• Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

  1995cited by this paper

• A new mouse model of typhoid fever using Salmonella enterica serovar Paratyphi C as a surrogate pathogen

  2026cites this paper
• Engineering liver disease models in vitro: emerging trends and innovations

  2025cites this paper
• Efficiency Enhancement of a Candidate Plague Vaccine by Incorporating Two Strains Attenuated at Distinct Molecular Targets

  2025cites this paper
• Mucosal COVID-19 vaccines in clinical development.

  2025cites this paper
• Efficiency enhancement of a candidate plague vaccine by inclusion into its composition of two strains, attenuated at different molecular targets

  2025cites this paper
• Innovative micro physiological systems for vaccine development

  2025cites this paper
• Oral tissue spheroid, organoid, and organ‐on chip microphysiological modeling strategies towards enhanced emulation of health and disease

  2025cites this paper
• A next-generation system for smoke inhalation integrated with a breathing lung-on-chip to model human lung responses to cigarette exposure

  2025cites this paper
• Exploring natural components in vaccine delivery systems: Types, routes of administration, in-vitro and in-vivo quantification techniques

  2025cites this paper
• A new dawn: Vitalising translational oncology research in Africa with the help of advanced cell culture models

  2025cites this paper
• Evidence Showing Childhood Vaccinations Are Causing Autism and Other Intellectual Disabilities

  2025cites this paper
• Assessment of In Vitro Models of the Human Buccal Mucosa for Vaccine and Adjuvant Development.

  2025cites this paper
• Advanced liver-on-chip model mimicking hepatic lobule with continuous microvascular network via high-definition laser patterning

  2025cites this paper
• Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?

  2025cites this paper
• Screening for variable drug responses using human iPSC cohorts

  2025cites this paper
• Autonomous Nucleic Acid and Protein Nanocomputing Agents Engineered to Operate in Living Cells

  2025cites this paper
• Vaccine Development for Severe Fever with Thrombocytopenia Syndrome Virus in Dogs

  2024cites this paper
• Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human Primates

  2024cites this paper
• Nontraditional models as research tools: the road not taken.

  2024cites this paper
• A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

  2024cites this paper
• Tonsil explants as a human in vitro model to study vaccine responses

  2024cites this paper
• Tissue-Engineered Three-Dimensional Platforms for Disease Modeling and Therapeutic Development

  2024cites this paper
• Next‐Generation Approaches for Biomedical Materials Evaluation: Microfluidics and Organ‐on‐a‐Chip Technologies

  2024cites this paper
• BLOC: buildable and linkable organ on a chip

  2024cites this paper
• Modeling Liver Development and Disease in a Dish

  2023cites this paper
• Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

  2023cites this paper
• Microfluidic devices for the detection of disease-specific proteins and other macromolecules, disease modelling and drug development: A review.

  2023cites this paper
• Design Considerations for Intratracheal Delivery Devices to Achieve Proof-of-Concept Dry Powder Biopharmaceutical Delivery in Mice

  2023cites this paper
• Human disease models in drug development

  2023cites this paper
• Integrated Electrochemical and Optical Biosensing in Organs‐on‐Chip

  2023cites this paper
• Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

  2023cites this paper
• Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models

  2022cites this paper
• Preclinical Animal Models for Q Fever Vaccine Development

  2022cites this paper
• Human organs-on-chips for disease modelling, drug development and personalized medicine

  2022cites this paper
• Tissue Engineering Approaches to Uncover Therapeutic Targets for Endothelial Dysfunction in Pathological Microenvironments

  2022cites this paper
• The urothelium: a multi-faceted barrier against a harsh environment

  2022cites this paper
• Ciprofloxacin exacerbates dysfunction of smooth muscle cells in a microphysiological model of thoracic aortic aneurysm

  2022cites this paper
• A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein

  2021cites this paper
• Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans

  2021cites this paper
• Nipah Virus Assays and Animal Models for Vaccine Development

  2021cites this paper
• Analyzing Macrophage Infection at the Organ Level.

  2021cites this paper
• Biomaterials, biological molecules, and polymers in developing vaccines.

  2021cites this paper
• Control Strategies for Carcinogenic-Associated Helminthiases: An Integrated Overview

  2021cites this paper
• A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species

  2021cites this paper
• Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response

  2021cites this paper
• Key Steps in Vaccine Development.

  2020cites this paper
• Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

  2020cites this paper
• Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines

  2020cites this paper
• Animal Models to Study Emerging Technologies Against SARS-CoV-2

  2020cites this paper
• Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection

  2020cites this paper
• MERS-CoV Standards, Assays and Animal Models for Vaccine Development

  2020cites this paper
• Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

  2020cites this paper
• A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults.

  2019cites this paper
• Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models

  2019influential citation
• Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.

  2019cites this paper
• Virus-Like-Vaccines against HIV

  2018cites this paper
• Modeling and optimizing the response to vaccines and immunotherapeutic interventions. Application to Ebola virus and HIV.

  2018cites this paper
• Universitet Virus-like-vaccines against HIV

  2018cites this paper
• Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.

  2018cites this paper